Company's FIELDS (Fields Ion Pairs/Hydrogen Bonds Electrostatics Linear Free-Energy Desolvation/Polar Scoring/Clustering) technology is an In-House proprietary ~4600 plus unique, novel fragments & scaffolds with proprietary RO3 criteria coupled with empirical Ki/Kd/IC50/EC50 data lead to the creation of training set of druggable clinical/disease relevant protein targets is a key behind the FIELDS technology. Our FIELDS approach rapidly aid our scientific team in selecting candidate ready compounds rapidly in to pre-clinical studies.